XML 55 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of Significant Accounting Policies - Segment Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Summary of Significant Accounting Policies      
Research and development $ 163,550 $ 118,011 $ 82,258
Single reportable segment      
Summary of Significant Accounting Policies      
Research and development 163,550 118,011 82,258
Single reportable segment | Barzolvolimab/Anti-KIT Program      
Summary of Significant Accounting Policies      
Research and development 123,750 79,913 51,220
Single reportable segment | CDX-622      
Summary of Significant Accounting Policies      
Research and development 17,341 16,299 5,613
Single reportable segment | CDX-585      
Summary of Significant Accounting Policies      
Research and development 2,813 6,357 9,793
Single reportable segment | Other Programs (a)      
Summary of Significant Accounting Policies      
Research and development $ 19,646 $ 15,442 $ 15,632